NCT02573363View on ClinicalTrials.gov

Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

October 7, 2015

Primary Completion Date

January 1, 2018

Study Completion Date

May 3, 2019

Conditions
Acute Myeloid Leukemia
Interventions
DRUG

Cytarabine

Given per standard of care

DRUG

Mitoxantrone Hydrochloride

Given per standard of care

DRUG

Selinexor

Given PO

Trial Locations (1)

60637

University of Chicago Comprehensive Cancer Center, Chicago

All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

lead

University of Chicago

OTHER

NCT02573363 - Selinexor With Combination Chemotherapy in Treating Patients With Acute Myeloid Leukemia | Biotech Hunter | Biotech Hunter